Want to see VVOS full AI Analyst Report?
VVOS Stock Chart & Stats
$0.22
<$0.01(2.52%)
At close: 4:00 PM EDT
$0.22
<$0.01(2.52%)
Day’s Range― - ―
52-Week Range$0.12 - $3.11
Previous CloseN/A
Volume131.13K
Average Volume (3M)5.93M
Market Cap
$4.53M
Enterprise Value$19.70M
Total Cash (Recent Filing)$1.77M
Total Debt (Recent Filing)$12.14M
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Nov 18, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.06
Shares Outstanding33,609,394
10 Day Avg. Volume2,752,284
30 Day Avg. Volume5,928,851
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)-14.00
Price to Sales (P/S)1.20
P/FCF Ratio-1.18
Enterprise Value/Market Cap4.35
Enterprise Value/Revenue0.94
Enterprise Value/Gross Profit1.58
Enterprise Value/Ebitda-0.87
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.03
Revenue Forecast (FY)$23.86M
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth And Gross MarginsRapid revenue growth alongside gross margins near 60% indicates improving commercial traction and underlying economics. If sustained, this combination can provide greater operating leverage, support investment in clinical expansion, and strengthen the company’s ability to scale beyond its current revenue base.
Expanded Sleep-Care CapacityThe Henderson expansion increases the company’s ability to serve patients through integrated sleep testing and treatment, creating a foundation for additional volume and recurring clinical revenue. Greater capacity also supports referral growth and helps convert local demand into revenue over the next several quarters.
Strategic Diagnostic IP PartnershipThe SOD transaction broadens Vivos beyond its existing oral-appliance offering by adding shared diagnostic intellectual property and potential access to large assisted-living, nursing-facility, and clinical channels. This could diversify revenue and create new treatment pathways if validation, approvals, and commercialization progress.
Bears Say
Persistent Cash Burn And Liquidity RiskContinued cash consumption materially limits financial flexibility and means operations and expansion depend on additional financing. With only about $1.8 million of cash and negative operating cash flow, the company has little buffer to absorb execution delays or fund its stated growth initiatives internally.
Severe UnprofitabilityThe scale of operating and net losses shows that current revenue is not yet sufficient to support the expense base. Unless growth translates into substantial operating leverage, persistent losses can consume capital, increase financing needs, and delay the company’s targeted path toward cash-flow positivity.
Declining Appliance Revenue MixLower appliance revenue despite higher unit volume indicates unfavorable mix and weaker revenue capture from the company’s core device business. This can constrain gross-profit dollars and make the broader growth strategy more dependent on newer service programs whose reimbursement, enrollment, and execution remain uncertain.
Vivos Therapeutics News
VVOS FAQ
What was Vivos Therapeutics’s price range in the past 12 months?
Vivos Therapeutics lowest stock price was $0.12 and its highest was $3.10 in the past 12 months.
What is Vivos Therapeutics’s market cap?
Vivos Therapeutics’s market cap is $4.53M.
When is Vivos Therapeutics’s upcoming earnings report date?
Vivos Therapeutics’s upcoming earnings report date is Nov 18, 2026 which is in 29 days.
How were Vivos Therapeutics’s earnings last quarter?
Vivos Therapeutics released its earnings results on Aug 14, 2026. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.41 by $0.1.
Is Vivos Therapeutics overvalued?
According to Wall Street analysts Vivos Therapeutics’s price is currently Overvalued.
Does Vivos Therapeutics pay dividends?
Vivos Therapeutics does not currently pay dividends.
What is Vivos Therapeutics’s EPS estimate?
Vivos Therapeutics’s EPS estimate is -0.3.
How many shares outstanding does Vivos Therapeutics have?
Vivos Therapeutics has 33,609,394 shares outstanding.
What happened to Vivos Therapeutics’s price movement after its last earnings report?
Vivos Therapeutics reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.41. Following the earnings report the stock price went down -12.245%.
Which hedge fund is a major shareholder of Vivos Therapeutics?
Currently, no hedge funds are holding shares in VVOS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vivos Therapeutics
Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.
VVOS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The call presented meaningful operational progress: solid revenue growth (Q2 +35%, YTD +51%), improving gross margins, tangible contributions from the Sleep Center of Nevada (sleep testing, treatment), and multiple identified recurring-revenue initiatives (remote monitoring, DME CPAP, EEG/insomnia, pediatric program). However, material financial challenges dominate the risk profile — rising operating losses and cost of sales, heavy cash burn ($9.2M YTD), just $1.8M of cash on hand, substantial doubt about the company’s ability to continue as a going concern, and non-compliance with NASDAQ equity requirements that could trigger delisting. Management’s path to cash-flow positivity by late 2026/early 2027 is plausible but highly execution-dependent and contingent on securing additional financing. Given the severity of near-term liquidity and regulatory (NASDAQ) risks despite operational momentum, the negatives weigh heavily.View all VVOS earnings summariesTechnical Analysis
Iridex
―
Co-Diagnostics
―
Adagio Medical Holdings
―
Envoy Medical
―
Nexalin Technology, Inc.
―
Ownership Overview
5.26% Insiders
0.93% Mutual Funds
0.10% Other Institutional Investors
93.53% Public Companies and
Individual Investors